SSRF Breakthrough Grant USD 125,000

International collaborative research into Synovial Sarcoma

Project description / Current Awarded Breakthrough Grant

The Synovial Sarcoma Research Foundation is focused on initiating and supporting high-quality basic and translational research in synovial sarcoma. This is one of the current projects that were awarded a “SSRF Breakthrough Grant”:

International collaborative research specifically targeted at Synovial Sarcoma

May, 2014 - May 2016 Canada – USA – The Netherlands

This International Collaborative Grant was created to develop a coordinated research program in Synovial Sarcoma by taking advantage of the resources and research capacity of an international team of clinician investigators and scientists.

This grant was co-funded by us, the Synovial Sarcoma Research Foundation, and the Liddy Shriver Sarcoma Initiative, each of which provided $125,000 in support. The two organizations are working together to initiate and support high-quality basic and translational research in synovial sarcoma.

The International SSRF Breakthrough Grant synovial sarcoma team has been working together for more than two years. The team is comprised of researchers from the Memorial Sloan Kettering Cancer Center in New York led by Drs. Marc Ladanyi and Scott Lowe, from the University of British Columbia in Vancouver led by Dr. Torsten Nielsen, and from Radboud University Medical Center in Nijmegen, Netherlands, led by Dr. Diederik de Bruijn.

The team met face-to-face in New York (August 2014), Philadelphia (April 2015), Salt Lake City (November 2015) and will meet in Lisbon (November 2016), and over the course of the ICG granting period has recruited additional expertise in the field through collaborations with Dr. Kevin Jones (Huntsman Cancer Institute, Salt Lake City) and Dr. Bertha Brodin (Karolinska Institutet, Stockholm). The research program has been able to achieve goal one, make significant progress on goal two after initial studies showed technical problems, and shifted goal three toward a more feasible murine system, while also branching into new research directions as novel findings and opportunities emerged.

Together, we are making a difference!

You can read the report now using the link at the bottom of this page.
 

Background and objectives

This $250,000 Grant on Synovial Sarcoma was co-funded by the Synovial Sarcoma Research Foundation Breakthrough Grant and the Liddy Shriver Sarcoma Initiative, each of which provided $125,000 in support.

The research project, which focuses on understanding the development of the disease, is a global effort of five investigators in three countries: Torsten O. Nielsen, MD, PhD, from the University of British Columbia in Canada, Scott W. Lowe, PhD and Marc Ladanyi, MD from the Memorial Sloan-Kettering Cancer Center in the United States and Diederik de Bruijn, PhD from the Radboud University Medical Center in The Netherlands.

This international collaborative research specifically targeted at Synovial Sarcoma has been initiated by the Synovial Sarcoma Research Foundation. It is bringing together resources and expertise from investigators in three countries in order to accelerate research into how the SS18-SSX oncogene causes synovial sarcoma, and what strategies might be able to block this process. Within this theme, the specific aims are:

  1. To use shRNA screening technology to interrogate epigenetic modifiers of gene expression that are likely to include critical partners contributing to SS18-SSX oncogenesis.
  2. To identify cofactors responsible for creating a permissive state for SS18-SSX oncogenesis, which might be exploited as therapeutic targets.
  3. To develop Zebrafish models of synovial sarcoma for validation and preclinical therapeutic translational studies.

This work will be enhanced by close collaborations with other scientists affiliated with the Memorial Sloan Kettering Cancer Center Sarcoma SPORE grant (from the NCI), the Centre for Molecular Life Sciences at Nijmegen University, the Centre for Translational and Applied Genomics and Underhill labs in Vancouver, and collaborators in the Utah sarcoma group.

Help Us fund these Amazing projects!

Every donation counts. Donate now.